A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide

A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide

Extragonadal androgens play a pivotal role in prostate cancer disease progression on androgen receptor signaling inhibitors (ARSi), including abiraterone and enzalutamide. We aimed to investigate if germline variants in genes involved in extragonadal androgen synthesis contribute to resistance to AR...

Full description

Bibliographic Details
Main Authors: Stefan A.J. Buck, Marinda Meertens, Frederiek M.F. van Ooijen, Esther Oomen-de Hoop, Evert de Jonge, Marieke J.H. Coenen, Andries M. Bergman, Stijn L.W. Koolen, Ronald de Wit, Alwin D.R. Huitema, Ron H.N. van Schaik, Ron H.J. Mathijssen
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Abiraterone
Enzalutamide
Germline variant
CYP11B1
Prostate cancer
Clinical outcome
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223016888

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223016888

Similar Items